Chronic Kidney Disease Stage 2
Understanding Chronic Kidney Disease Stage 2 (CKD Stage 2) diagnosis, documentation, and medical coding? Learn about CKD Stage 2 symptoms, GFR ranges, treatment options, and clinical guidelines. Find information on Mild Chronic Kidney Disease management and best practices for healthcare professionals involved in diagnosis and care. This resource offers insights into accurate ICD-10 coding for CKD Stage 2 and relevant medical terminology for clear and concise clinical documentation.
Mildly reduced kidney function, often with no symptoms.
Slightly elevated creatinine and protein in urine. May have high blood pressure.
Primary care, nephrology clinics, routine check-ups.
ICD-10 Code Families
Complete code families applicable to N18.2
When to use each related code
| Description | When to use |
|---|---|
| Mildly reduced kidney function. | Use CKD Stage 2 when eGFR is 60-89 mL/min/1.73m2 and other markers confirm chronic kidney damage. |
| Moderately reduced kidney function. | Use CKD Stage 3A when eGFR is 45-59 mL/min/1.73m2 with confirmed chronic kidney damage. |
| Severely reduced kidney function. | Use CKD Stage 3B when eGFR is 30-44 mL/min/1.73m2 with confirmed chronic kidney damage. |
Best-practice checklist
- ✓Document GFR 60-89 mL/min/1.73 m2
- ✓Confirm CKD diagnosis with two GFR tests ≥90 days apart
- ✓Document cause of CKD (e.g., diabetes, hypertension)
- ✓Specify current stage (CKD Stage 2) and related symptoms
- ✓Note relevant comorbidities and current treatment plan
Common pitfalls to avoid
Coding CKD stage 2 without documented GFR or albuminuria lacks specificity and may lead to incorrect reimbursement.
Overlapping conditions like hypertension and diabetes must be accurately documented for proper CKD stage 2 coding and risk adjustment.
Coding CKD stage 2 based on a single abnormal lab value without confirmatory testing can result in inaccurate coding and clinical documentation improvement issues.
Best-practice tips
- 01Control hypertension: Optimize ACEi/ARB meds, document BP control.
- 02Reduce proteinuria: Monitor urine ACR, adjust diet, code accurately.
- 03Manage diabetes: Optimize A1C, adhere to guidelines, ensure CDI.
- 04Lifestyle changes: Smoking cessation, weight management, compliant documentation.
- 05Regular monitoring: eGFR, creatinine, electrolytes, follow CKD stage 2 guidelines.
Step-by-step checklist
- 1
Verify eGFR 60-89 mL/min/1.73 m2 for 3+ months (ICD-10 N18.2)
- 2
Confirm albuminuria or other CKD marker documented (LOINC)
- 3
Document cause of CKD and relevant comorbidities (SNOMED CT)
- 4
Review medications for nephrotoxicity; adjust as needed
- 5
Educate patient on CKD management, diet, and follow-up
Ready-to-paste narrative
Patient presents with chronic kidney disease stage 2 (CKD stage 2), also known as mild chronic kidney disease. Diagnosis is based on an estimated glomerular filtration rate (eGFR) between 60-89 mL/min/1.73 m2, persisting for at least three months. Patient's current eGFR is [insert value] mL/min/1.73 m2, confirmed by [specify test, e.g., serum creatinine-based CKD-EPI equation] on [date]. Relevant lab results include [list relevant serum creatinine, BUN, urine albumin-to-creatinine ratio (ACR), and other relevant labs with dates and values]. Patient's medical history includes [list relevant comorbidities, e.g., hypertension, diabetes, family history of CKD]. Review of systems reveals [document pertinent positives and negatives, e.g., presence or absence of fatigue, edema, changes in urination]. Physical examination findings are within normal limits except for [document any relevant findings]. Assessment includes chronic kidney disease stage 2 (ICD-10 code N18.2). Plan includes monitoring renal function with regular eGFR calculations and urinalysis, management of underlying conditions such as [mention specific condition management, e.g., blood pressure control with antihypertensive medications, glycemic control with diabetes medications], patient education on renal diet, and lifestyle modifications including [specify recommendations, e.g., sodium restriction, fluid management, regular exercise]. Follow-up scheduled in [timeframe] to reassess renal function and adjust management as needed. Differential diagnoses considered included acute kidney injury (AKI), and other causes of decreased GFR. This documentation supports medical necessity for continued monitoring and treatment of chronic kidney disease.
Common questions and answers
What are the most effective strategies for managing Chronic Kidney Disease Stage 2 in patients with comorbid hypertension?+
Managing Chronic Kidney Disease Stage 2 (CKD Stage 2) with comorbid hypertension requires a multifaceted approach focused on both slowing CKD progression and controlling blood pressure. Key strategies include optimizing antihypertensive therapy, often with ACE inhibitors or ARBs due to their renoprotective effects, alongside lifestyle modifications such as dietary sodium restriction and weight management. Tight blood pressure control, typically aiming for a target below 130/80 mmHg, is crucial in these patients to minimize further kidney damage. Explore how combining pharmacological interventions with lifestyle changes can improve patient outcomes in CKD Stage 2 with hypertension. Consider implementing regular monitoring of kidney function (eGFR and urine albumin) and blood pressure to assess treatment efficacy and adjust management as needed.
How can I differentiate Chronic Kidney Disease Stage 2 (CKD Stage 2) from acute kidney injury (AKI) in a clinical setting, considering both present similar symptoms and elevated creatinine levels?+
Differentiating Chronic Kidney Disease Stage 2 (CKD Stage 2) from acute kidney injury (AKI) can be challenging due to overlapping symptoms and similar lab findings like elevated creatinine. However, key distinctions lie in the timeframe and clinical history. AKI typically presents with a rapid decline in kidney function over hours or days, often associated with a clear precipitating factor such as infection, dehydration, or nephrotoxic medication use. CKD Stage 2, on the other hand, is characterized by a gradual decline in kidney function over months or years, often without overt symptoms in early stages. A thorough patient history, including past medical records, medication lists, and recent illnesses, is essential for accurate diagnosis. Furthermore, assessing for structural kidney abnormalities through imaging studies and evaluating for proteinuria can help differentiate CKD from AKI. Learn more about using a combination of clinical history, laboratory data, and imaging findings for accurate differential diagnosis between CKD Stage 2 and AKI.
What are the recommended guidelines for monitoring disease progression and adjusting treatment plans in patients diagnosed with Mild Chronic Kidney Disease (CKD Stage 2)?+
Monitoring disease progression in Mild Chronic Kidney Disease (CKD Stage 2) is essential for timely intervention and preventing further decline in kidney function. Current guidelines recommend regular monitoring of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) every 3 to 6 months. These tests provide crucial information about kidney function and the presence of kidney damage. Furthermore, regular blood pressure monitoring and assessment of cardiovascular risk factors are important aspects of managing CKD Stage 2 patients. Based on the patient's individual risk profile and disease progression, treatment plans may need adjustment. This may involve intensifying blood pressure control, optimizing management of comorbidities like diabetes and hypertension, or addressing lifestyle factors such as diet and exercise. Consider implementing a patient-centered approach to monitoring and treatment adjustments to enhance patient engagement and optimize long-term outcomes in CKD Stage 2 management.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.